Completed Public Health & Healthcare

North West HTMR

In plain English

AI plain-English summary

A new centre will investigate how to make clinical trials more reliable, efficient, and patient-focused. Randomised controlled trials are the gold standard for comparing treatments, but they come with practical challenges. Early-stage drug testing must proceed through careful phases, and later-stage trials require researchers to decide which outcomes matter most—a choice that should balance clinical priorities with what patients actually care about. Currently, there is no dedicated hub where these methodological problems are systematically studied and solved. This centre will bring together experts to research the design, conduct, and analysis of clinical trials. It will address questions such as how to stage drug development efficiently and how to select meaningful outcome measures that reflect both medical and patient perspectives. The goal is to strengthen the evidence base that underpins healthcare decisions. If successful, the centre could improve the quality of clinical trials across the UK, leading to more trustworthy comparisons of treatments. Patients would benefit indirectly, because doctors would have better evidence to guide prescribing, surgery, or other care. The work targets the infrastructure of medical research itself—the quiet machinery that determines whether a new drug truly works—rather than any single disease or therapy.

View original technical description
The best method for finding out whether one treatment is better than another is to perform a research study known as a randomised controlled trial, in which treatments are allocated to patients at random, rather like throwing a dice to decide. Studies like this are not without their difficulties. For example, when drugs are first trialled, the research should proceed in stages with evaluation at each stage. As treatments move into the later phases of study, researchers must choose which outcomes are most important to measure, a decision ideally arrived at through consideration of both the clinical and patient perspective. This proposal is to create a world-class centre where issues such as these facing the clinical trials community can be investigated, the overall aim being to improve patient care by improving the evidence on which decisions about healthcare are based.

View the original record at the funder ↗

Researchers

Ann Jacoby (Co-Investigator)Anthony Marson (Co-Investigator)Bridget Young (Co-Investigator)Carrol Gamble (Co-Investigator)Catrin Tudur Smith (Co-Investigator)Dyfrig Hughes (Co-Investigator)John Neoptolemos (Co-Investigator)John Whitehead (Co-Investigator)Munir Pirmohamed (Co-Investigator)Patricia Whitehead (Co-Investigator)Paula Williamson (Principal Investigator)Peter Bower (Co-Investigator)Rosalind Smyth (Co-Investigator)

Related Research

Grants with similar aims, by meaning.

Assessing methods to specify the targeted difference for a randomised controlled trial
Developing efficient perpetual platform trials to study multiple treatments and multiple biomarkers
Method - Design
MRC North West Hub for Trials Methodology Research
Randomised trials

Original classification

Research Grant

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.